The effect of flurbiprofen [2-(2-fluoro-4-biphenylyl) propionic acid] on platelet function and blood coagulation
| Autor: | T. Davies, G.P. McNicol, Dorothy A. Lederer, Ann A. Spencer |
|---|---|
| Rok vydání: | 1974 |
| Předmět: |
Adult
Male Epinephrine Platelet Aggregation Flurbiprofen Anti-Inflammatory Agents Administration Oral Pharmacology Platelet Adhesiveness Thrombin Bleeding time Thromboembolism Platelet adhesiveness medicine Humans Platelet Carbon Radioisotopes Blood Coagulation medicine.diagnostic_test Chemistry Platelet Factor 3 Biphenyl Compounds Fluorine Hematology Blood Cell Count Adenosine Diphosphate Coagulation Biochemistry Prothrombin Time Blood Coagulation Tests Collagen Serotonin Antagonists Propionates medicine.drug Partial thromboplastin time |
| Zdroj: | Thrombosis Research. 5:667-683 |
| ISSN: | 0049-3848 |
| DOI: | 10.1016/0049-3848(74)90056-5 |
| Popis: | Flurbiprofen, a new anti-inflammatory compound, inhibits platelet aggregation in response to collagen and thrombin, and blocks the release of 14C-serotonin. In vivo , in 8 normal volunteers, a single oral dose (50mg.) inhibited platelet aggregation to collagen, ADP and adrenaline, blocked the release of 14C-serotonin and impaired platelet factor 3 availability. There were no effects on prothrombin time, partial thromboplastin time, euglobulin lysis activity of plasma, platelet count, platelet adhesiveness or bleeding time. The effects of the drug on platelet aggregation had largely disappeared 24 hours following administration but gross inhibition could be shown up to 7.5 hours after ingestion. The collagen-induced aggregation response and 14C-serotonin release of platelets showed an inverse relationship to serum concentration of the drug. The results suggest that flurbiprofen merits further study as a potential therapeutic agent in the management of thromboembolic disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|